HomeBIOTECHNOLOGY
BIOTECHNOLOGY
Medical Device News Magazine reports breaking biotechnology news in addition to medical device news.
International Consortium to Revolutionize Viral Vector Manufacturing | Reports VVector Bio
"This project represents a paradigm shift towards improving viral vector manufacturing yields," remarked Alina Venereo Sanchez, CEO of VVector Bio. "By integrating genomics, epigenomics, transcriptomics, metabolomics and new ways of directly integrating analytics into production, we're poised to unlock unprecedented production capabilities."
Qubit Pharmaceuticals nominated for “Best start-up 2024” award by Prix Galien USA
Qubit Pharmaceuticals has been nominated for the 2024 edition of the prestigious Prix Galien USA, in the "Best Startup" category, out of a field of 41 companies, including 15 French contenders.
TEPKINLY (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic
HT-KIT cancer therapeutic is an antisense oligonucleotide that targets the proto-oncogene cKIT being developed for the treatment of mast cell-derived cancers and anaphylaxis and previously received Orphan Drug Designation from FDA.
NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines
NEC Bio Therapeutics, a Mannheim based German company focused on clinical development of innovative drugs by using proprietary AI, is developing NECVAX-NEO1, a personalized cancer vaccine that uses cutting-edge AI/machine learning technology to target specific tumor neoantigens that are unique to each patient. NECVAX-NEO1 relies on powerful and flexible plug and play bacteria-based platform technology and is convenient for patients due to its oral delivery. Unlike traditional treatments, NECVAX-NEO1 requires tailored manufacturing capacities and is produced by cost-efficient microbial fermentation at a small scale and with a quick turnaround time.
Top Scientists Shaping the Biopharma Industry
This article highlights some of the top scientists shaping the biopharma industry and their contributions to the field.
Rejuvenate Biomed and SAS Tap AI to Develop Disease-agnostic Drug Repurposing Discovery Tools
"Our partnership with SAS amplifies the core strengths of both our R&D teams," Dr. Ann Beliën, Founder and Chief Executive Officer of Rejuvenate Biomed. "By embracing this partnership and leveraging the capabilities of SAS Viya, we expect to meaningfully de-risk and accelerate the development of our internal portfolio while enhancing our discovery platform and partnering capabilities."
Flagship Pioneering Unveils Abiologics to Pioneer Supranatural Biologics, A New Biotherapeutic Class
"For the first time, we are able to imagine and generate chemically synthesized biologics at scale and with increasing programmability, offering a new class of medicines with transformative potential," said Avak Kahvejian, Ph.D., Co-Founder and CEO of Abiologics and General Partner at Flagship Pioneering. "Creating protein biologics with artificial building blocks rather than naturally occurring amino acids allows Synteins to go unrecognized by the immune system, offering significant advantages compared to today's biologics such as less frequent dosing, oral delivery and the ability to reach parts of the body that were previously impossible to access and treat. With Synteins, Abiologics is poised to bring boundary-breaking medicines to patients across a range of diseases."
Biolyst Scientific Announces New Brand Name to Encompass EMS and Azer | Will Deepen Offerings to Clinical and Research Lab Customers
The new name, ‘Biolyst,’ reflects the essential part the company plays in the Life Sciences discoveries that make life better for all. ‘Bio’ signals where impact is felt – in enhancing and extending life – and ‘lyst’ signifies its role as catalyst in helping clinical and research labs pursue breakthroughs with accuracy and efficiency. The EMS and Azer brand names will continue to exist as ‘power brands’ within the product portfolio.